Table 2 An overview of different types of iPSCs and their characteristics
From: Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
iPSC Line | Origin of cells used for iPSC generation | Method of iPSC Generation | Differentiation Potential | Characteristics | Functions | Limitations | References |
|---|---|---|---|---|---|---|---|
HiPSC | Human somatic cells | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Cell replacement therapy, drug discovery | Epigenetic memory, variability in differentiation potential | [54] |
MiPSC | Mouse somatic cells | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Disease modeling, developmental biology | Tumorigenic potential, incomplete reprogramming | [55] |
CiPSC | Chimpanzee fibroblasts | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Comparative genomics, conservation biology | Limited availability, ethical considerations | [56] |
siPSC | Porcine somatic cells | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Xenotransplantation, agriculture | Limited availability, ethical considerations | [57] |
EpiSC | Mouse or human embryonic cells | Epiblast stem cells | Limited differentiation potential | Expression of pluripotency markers | Developmental biology, tissue engineering | Unstable in culture, low efficiency of reprogramming | [58] |
FiPSC | Feline somatic cells | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Disease modeling, regenerative medicine | Limited availability, ethical considerations | [59] |
NiPSC | Canine somatic cells | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Regenerative medicine, veterinary research | Limited availability, ethical considerations | [60] |
ViPSC | Viral vectors | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Gene therapy, disease modeling | Safety concerns, potential for viral integration | [61] |
CiPSC | Chemical compounds | Chemical-induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Disease modeling, regenerative medicine | Limited efficiency, potential toxicity | [21] |
SiPSC | Synthetic transcription factors | Synthetic-induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Disease modeling, drug discovery | Limited efficiency, potential off-target effects | [62] |
AiPSC | Human amniotic fluid cells | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Cell replacement therapy, disease modeling | Limited availability, potential for genetic abnormalities | [63] |
PiPSC | Porcine pluripotent stem cells | Genetic engineering | Multilineage | Expression of pluripotency markers | Tissue engineering, regenerative medicine | Limited availability, ethical considerations | [64] |
GiPSC | Germline cells | Induced pluripotent stem cells | Limited differentiation potential | Expression of germline markers | Reproductive biology, disease modeling | Ethical concerns, low efficiency | [65] |
LiPSC | Lipoblasts | Induced pluripotent stem cells | Adipogenic differentiation | Expression of adipogenic markers | Adipose tissue engineering, disease modeling | Limited differentiation potential | [63] |
XiPSC | Xenopus tropicalis tadpole cells | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Developmental biology, regeneration research | Limited availability, potential ethical considerations | [64] |
NiPSC | Neonatal foreskin fibroblasts | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Disease modeling, regenerative medicine | Limited availability | [66] |
TiPSC | Testicular cells | Induced pluripotent stem cells | Limited differentiation potential | Expression of germline markers | Reproductive biology, disease modeling | Ethical concerns, low efficiency | [47] |
ZiPSC | Zebrafish embryos | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Developmental biology, regeneration research | Limited availability, potential ethical considerations | [67] |
AiPSC | Adult neural stem cells | Induced pluripotent stem cells | Neural differentiation | Expression of neural markers | Neural regeneration, disease modeling | Limited differentiation potential | [68] |
DiPSC | Dental pulp stem cells | Induced pluripotent stem cells | Mesenchymal differentiation | Expression of mesenchymal markers | Dental tissue engineering, disease modeling | Limited differentiation potential | [42] |
CiPSC | Corneal stromal cells | Induced pluripotent stem cells | Corneal differentiation | Expression of corneal markers | Corneal tissue engineering, disease modeling | Limited differentiation potential | [43] |
AiPSC | Aortic endothelial cells | Induced pluripotent stem cells | Endothelial differentiation | Expression of endothelial markers | Vascular tissue engineering, disease modeling | Limited differentiation potential | [44] |
OiPSC | Ovarian surface epithelial cells | Induced pluripotent stem cells | Limited differentiation potential | Expression of ovarian markers | Reproductive biology, disease modeling | Limited differentiation potential | [45] |
SiPSC | Skeletal muscle cells | Induced pluripotent stem cells | Myogenic differentiation | Expression of myogenic markers | Skeletal muscle tissue engineering, disease modeling | Limited differentiation potential | [46] |
TiPSC | Tonsil-derived cells | Induced pluripotent stem cells | Multilineage | Expression of pluripotency markers | Disease modeling, regenerative medicine | Limited availability | [47] |
FiPSC | Fat-derived cells | Induced pluripotent stem cells | Adipogenic differentiation | Expression of adipogenic markers | Adipose tissue engineering, disease modeling | Limited differentiation potential | [48] |
LiPSC | Liver cells | Induced pluripotent stem cells | Hepatic differentiation | Expression of hepatic markers | Liver tissue engineering, disease modeling | Limited differentiation potential | [49] |
RiPSC | Retinal pigment epithelial cells | Induced pluripotent stem cells | Retinal differentiation | Expression of retinal markers | Retinal tissue engineering, disease modeling | Limited differentiation potential | [69] |
KiPSC | Kidney cells | Induced pluripotent stem cells | Renal differentiation | Expression of renal markers | Renal tissue engineering, disease modeling | Limited differentiation potential | [70] |
SiPSC | Salivary gland-derived cells | Induced pluripotent stem cells | Limited differentiation potential | Expression of salivary gland markers | Salivary gland tissue engineering, disease modeling | Limited differentiation potential | [71] |
LiPSC | Liver cells | Induced pluripotent stem cells | Hepatic differentiation | Expression of hepatic markers | Liver tissue engineering, disease modeling | Limited differentiation potential | [70] |
RiPSC | Retinal pigment epithelial cells | Induced pluripotent stem cells | Retinal differentiation | Expression of retinal markers | Retinal tissue engineering, disease modeling | Limited differentiation potential | [70] |
KiPSC | Kidney cells | Induced pluripotent stem cells | Renal differentiation | Expression of renal markers | Renal tissue engineering, disease modeling | Limited differentiation potential | [72] |
SiPSC | Salivary gland-derived cells | Induced pluripotent stem cells | Limited differentiation potential | Expression of salivary gland markers | Salivary gland tissue engineering, disease modeling | Limited differentiation potential | [70] |